3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
4
Genitourinary
3
Head & Neck
2
Gynecologic
2
Gastrointestinal
2
Endocrine
2
CNS
2
Breast
2
Thoracic
1
NET
1
Lymphoid
1
Dermatologic
1
Conditions
Brain Neoplasms
4
Glioma
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Large-Cell, Anaplastic
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
16
Filgrastim
15
Etoposide
10
Carboplatin
10
Peripheral Blood Stem Cell Transplantation
8
Melphalan
8
Magnetic Resonance Spectroscopy
7
Granulocyte Colony-Stimulating Factor
7
Busulfan
7
Thiotepa
6
Temozolomide
6
Radiotherapy
6
Ifosfamide
6
etoposide phosphate
5
X-Rays
5
Topotecan
5
Phantoms, Imaging
5
Doxorubicin
5
Cisplatin
5
Vincristine
4
Specimen Handling
4
Nuclear Medicine Department, Hospital
4
Mesna
4
selpercatinib
3
sargramostim
3
pembrolizumab
3
palbociclib
3
aldesleukin
3
Sirolimus
3
Radiosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Sarcoma
×
entrectinib
×
CNS
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA